Late in 2023, the White House released draft guidance outlining proposed factors that an agency may consider, including the “reasonableness of a product’s price,” when deciding whether to exercise its “march-in rights” to federally funded inventions under the Bayh-Dole Act. This would be an unprecedented step and the legislation was never intended to be used this way. According to key stakeholders, this will negatively affect innovation across the spectrum of life sciences – from universities and federal R&D labs, to startups, big pharma, investors, and ultimately patients.

Please join us as we explore the impact of the Bayh-Dole Act on the life sciences sector and what this threat may mean for companies going forward.

There will not be a Zoom option for this session.